on INNATE PHARMA (EPA:IPH)
Innate Pharma: Investment of 7.9 million dollars for IPH6501
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce an investment of up to $7.9 million to develop IPH6501 in follicular lymphoma. Innate will receive $3 million in upfront payments and up to an additional $4.9 million in contingent tranches.
The ongoing Phase 1/2 clinical trial will evaluate the safety and efficacy of IPH6501 in patients with CD20-positive non-Hodgkin lymphoma. IFLI will invest in new Innate shares, representing 2.26% of its capital, to support this project.
This partnership aims to offer new therapeutic options for patients affected by lymphoma, thus strengthening collaborations in the field of oncology.
R. H.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all INNATE PHARMA news